Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
CAMBRIDGE, Mass., Feb. 15, 2017 -- Intellia Therapeutics, Inc. (Nasdaq:NTLA) will hold a conference call with investors on Thursday, February 16, 2017 at 8 a.m., EST. Investors are invited to dial into the conference call hosted by Nessan Bermingham, Ph.D., chief executive officer and founder, Jose E. Rivera, executive vice president and general counsel, and Graeme Bell, chief financial officer.
To participate on the day of the call, dial 844-882-7840 and use Conference ID# 74650186, approximately five minutes before the call. International callers, please dial +1 574-990-9827 and use Conference ID# 74650186.
The call will be available for replay from February 16 to March 18, 2017. The replay number is 855-859-2056, Conference ID# 74650186. International callers, please dial +1 404-537-3406, Conference ID# 74650186.
About Intellia Therapeutics
Intellia Therapeutics is a leading genome editing company, focused on the development of proprietary, potentially curative therapeutics using the CRISPR/Cas9 system. Intellia believes the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. Our combination of deep scientific, technical and clinical development experience, along with our leading intellectual property portfolio, puts us in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Learn more about Intellia Therapeutics and CRISPR/Cas9 at intelliatx.com; Follow us on Twitter @intelliatweets.
Media Contact: Jennifer Mound Smoter Senior Vice President, External Affairs & Communications (857) 706-1071 [email protected] Investor Contact: Graeme Bell Chief Financial Officer +1 857-706-1081 [email protected]
